Loading...
Docoh

Immucell (ICCC)

ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain™, a novel treatment for subclinical mastitis without a milk discard requirement that provides an alternative to traditional antibiotics.

ICCC stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 11.04M 11.04M 11.04M 11.04M 11.04M 11.04M
Cash burn (monthly) 257.97K (no burn) 227.67K (no burn) (no burn) (no burn)
Cash used (since last report) 369.47K n/a 326.07K n/a n/a n/a
Cash remaining 10.67M n/a 10.72M n/a n/a n/a
Runway (months of cash) 41.4 n/a 47.1 n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 8.25 400 3.3K 94,019
14 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 8.05 50 402.5 93,619
14 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 8.1 200 1.62K 93,569
13 Jun 22 David Cunningham Common stock $0.10 per value per share Buy Acquire P No No 8 1,000 8K 16,000
13 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 7.77 485 3.77K 93,369
13 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 7.82 48 375.36 92,884
13 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 7.79 90 701.1 92,836
13 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 7.81 462 3.61K 92,746
13 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 7.8 200 1.56K 92,284
13 Jun 22 David Scott Tomsche Common stock $0.10 per value per share Sale back to company Acquire D No No 7.73 200 1.55K 92,084
12.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 27 30 -10.0%
Opened positions 0 4 EXIT
Closed positions 3 2 +50.0%
Increased positions 9 5 +80.0%
Reduced positions 10 9 +11.1%
13F shares Current Prev Q Change
Total value 22.68M 26.55M -14.6%
Total shares 951.57K 924.34K +2.9%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Vanguard 204.33K $1.97M +22.2%
Renaissance Technologies 154.58K $1.49M -7.8%
Meristem Family Wealth 85.52K $825K 0.0%
Shufro Rose & Co 82.05K $792K +358.1%
Bleichroeder 71.07K $686K +14.2%
MS Morgan Stanley 66.77K $644K +18.2%
Overbrook Management 45.88K $443K -39.2%
Perritt Capital Management 36.49K $352K -8.8%
Strategic Financial Services, Inc, 31K $299K +3.2%
Geode Capital Management 22.67K $218K +1.0%
Largest transactions Shares Bought/sold Change
Shufro Rose & Co 82.05K +64.14K +358.1%
Aries Wealth Management 0 -44.1K EXIT
Vanguard 204.33K +37.08K +22.2%
Overbrook Management 45.88K -29.59K -39.2%
Renaissance Technologies 154.58K -13.04K -7.8%
MS Morgan Stanley 66.77K +10.3K +18.2%
Bleichroeder 71.07K +8.82K +14.2%
Perritt Capital Management 36.49K -3.51K -8.8%
Essex Financial Services 11K -1.72K -13.5%
Captrust Financial Advisors 1.2K +1K +500.0%

Financial report summary

?
Competition
PfizerZoetis
Management Discussion
  • As detailed in Note 17, “Segment Information”, to the accompanying unaudited financial statements, we operate in two business segments. The Scours segment is dedicated to manufacturing and selling First Defense®, a product used to prevent scours in newborn calves, which is regulated by the USDA. The Mastitis segment is focused on developing and commercializing Re-Tain®, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the FDA.
  • Through both continued growth in sales of the First Defense® product line and a successful launch of Re-Tain® as soon as possible, and with a measured approach to expanding our customer-facing staff, it is our objective to increase our current annual level of total product sales of approximately $19.2 million for the year ended December 31, 2021 to approximately $23 million or more by the year ending December 31, 2023. As additional resources are dedicated to production, sales, marketing and technical services, our longer-term goal is to exceed $35 million of annual total product sales as soon as possible during the five-year period after the market launch of Re-Tain®.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Good
New words: abstained, bacterial, birth, brand, breakthrough, broker, buffer, caught, comment, competitor, crop, crucial, differentiating, displace, divert, encouraged, erasing, escalate, feature, frame, fueled, guarantee, healthy, house, inconsistency, inconsistent, intent, internationally, landlord, leader, livestock, message, morbidity, mortality, norm, notify, pharma, plastic, polyclonal, profile, proven, proximity, recession, recessionary, reminded, research, resolve, resolved, satisfaction, Secondarily, shed, shell, substantive, therapeutic, thing, thirty, transform, true, type, unprotected, Urban, worthy
Removed: accept, batch, deductible, dumped, encountered, executing, extending, forgiven, immunize, implemented, involuntary, legacy, lifting, lunch, pace, Paycheck, payroll, peak, pivotal, PPP, preceding, purified, recurrence, reinspection, repeatability, school, senior, setback, slightly, swap, TD, temporarily, variance